Relapsed Clinical Trials in Beijing, Beijing Municipality
37 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 37 trials
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
MCLRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Peking University Third Hospital43 enrolled1 locationNCT07460362
Recruiting
Phase 3
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.120 enrolled1 locationNCT06776952
Recruiting
Phase 3
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.130 enrolled1 locationNCT06122389
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 2
Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)
Peking University People's Hospital56 enrolled1 locationNCT06869265
Recruiting
Not Applicable
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL+1 more
Peking University People's Hospital130 enrolled1 locationNCT06581081
Recruiting
Phase 1Phase 2
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences20 enrolled1 locationNCT06834529
Recruiting
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253
Recruiting
Phase 1Phase 2
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
Relapsed Peripheral T-Cell LymphomasRefractory Peripheral T-Cell Lymphomas
Navy General Hospital, Beijing52 enrolled1 locationNCT06176027
Recruiting
Phase 2
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Minimal Residual DiseaseMyelodysplastic SyndromesRefractory Acute Myeloid Leukemia+1 more
Beijing 302 Hospital67 enrolled1 locationNCT06536959
Recruiting
Phase 2
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Chongqing Precision Biotech Co., Ltd100 enrolled10 locationsNCT05334823
Recruiting
Phase 1
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled2 locationsNCT06445517
Recruiting
Phase 2
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Refractory Classic Hodgkin LymphomaRelapsed Classic Hodgkin Lymphoma
Navy General Hospital, Beijing40 enrolled1 locationNCT06190067
Recruiting
Phase 1Phase 2
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT05896046